The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers

British Journal of Clinical Pharmacology

Volumn 41, Issue 2, 1996, Pages 141-147

  Seaber, E ^a   On, N ^a   Phillips, S ^a   Churchus, R ^a   Posner, J ^a   Rolan, P ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

311C90; First administration; Pharmacokinetics; Tolerability

Indexed keywords

ANTIMIGRAINE AGENT; DRUG METABOLITE; PLACEBO; SEROTONIN 1D RECEPTOR; ZOLMITRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MIGRAINE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0030062503     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00172.x     Document Type: Article

References (9)

1. Goldstein ME, Chen TC. The epidemiology of disabling headache. Adv Neurol 1982; 33: 377-390.
2. Humphrey P, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991; 12: 444-445.
3. Moskowitz NA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13: 307-311.
4. Kaube H, Hoskin K, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109: 788-792.
5. 1D agonist 311C90. Headache 1994; 34: 394-399.
6. 1D receptor agonist 311C90. New Advances in Headache Research 1994; 4: 3-4.
7. G Plosker, D McTavish. Sumatriptan: A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47: 622-651.
8. Dechant KL, Clissold SP. Sumatriptan - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992; 43: 776-798.
9. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-294.